Malcolm K. Brenner - Nanotechnology

Author Information

Malcolm K. Brenner is affiliated with the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital, and Texas Children's Hospital in Houston, TX, USA. His research focuses on the development and clinical implementation of genetically modified immune cells for cancer therapy, with a particular emphasis on T-cell therapies.

Research Contributions

Malcolm K. Brenner has made significant contributions to the field of immunotherapy, particularly in the use of CAR-T cells and other genetically modified immune effectors to treat various types of cancer. His research includes evaluating the safety and efficacy of these therapies, as well as developing methods to improve their effectiveness and reduce potential adverse effects. Some of his recent work involves novel approaches to enhance the safety of iPSC-derived T cell therapy and exploring the use of oncolytic immunotherapy to boost CAR-T cell antitumor activity.

Aliases

Malcolm K. Brenner is also known by several aliases, including:

Malcolm K. Brenner M. K. Brenner M.k. Brenner Malcolm K Brenner M K Brenner M.k Brenner Malcolmk. Brenner M Brenner M. Brenner Malcolm Brenner

Publication and Citation Metrics

Metric	Value
Total Citation Count	46,613
H-index	110
Total Number of Papers	798

Publications:

Long Term Follow up for the Development of Subsequent Malignancies in Patients Treated with Genetically Modified Immune Effectors

DOI: 10.1016/s2666-6367(22)00406-7

Year: 2022

Evaluating the Safety and Clinical Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

DOI: 10.1016/s2666-6367(22)00187-7

Year: 2022

Donor-Derived Multiple Leukemia Antigen Specific T-cell Therapy to Prevent Relapse Post-Transplant in Patients with ALL.

DOI: 10.1182/blood.2021014648

Year: 2022

Safety and Tolerability of Administering Leukemia-Specific Donor T Cells (mLSTs) after Allogeneic Transplant to Pediatric Patients with AML/MDS

DOI: 10.1016/s2666-6367(22)00442-0

Year: 2022

Improving the safety of iPSC-derived T cell therapy

DOI: 10.1016/b978-0-323-90059-1.00010-5

Year: 2022

Phase I Trial of GD2.CAR T Cells Combined with a Novel Interleukin-7 Signal Modulator

DOI: 10.1016/s2666-6367(22)00290-1

Year: 2022

Taking T-Cell Oncotherapy Off-the-Shelf.

DOI: 10.1016/j.it.2021.01.004

Year: 2021

Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors

DOI: 10.1038/s42003-021-01914-8

Year: 2021

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

DOI: 10.1182/blood-2021-154142

Year: 2021

Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.

DOI: 10.1016/j.ymthe.2021.02.004

Year: 2021

What is Single Particle Spectroscopy?

What Resources Are Available for Students?

What is Magnetoresistance?

What is the Role of Lithography in Semiconductor Manufacturing?

What is Open Source Information?

How is Intel Addressing These Challenges?

What is Strain?

What are Some Key Applications of Nanotechnology in Defense?

What are Alveolar Regions?

What Techniques are Used in Nanoscale Design?

Partnered Content Networks

Relevant Topics